On Tuesday, Bioventus Inc. (NASDAQ:BVS) reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.
The medical device company reported sales of $153.6 million, up 13.5% year over year, beating the consensus of $145.2 million, driven by double-digit growth in pain treatments and surgical solutions.
Pain treatment sales increased 18.7% to $62.8 million, Surgical Solutions sales increased 16.8% to $46.43 million and Restorative Therapies sales fell marginally by 0.6% to $25.95 million.
Net loss from continuing operations was $0.3 million, compared to $7.7 million a year ago. Adjusted EBITDA from continuing operations of $28.3 million advanced 28.3% from $22.0 million last year due to strong revenue growth and adjusted gross margin expansion.
Also Read: Ferguson Stock Drops As Q2 EPS Miss, Margin Squeeze Overshadow Sales Growth
In the fourth quarter, the company strengthened its balance sheet and improved liquidity by reducing long-term debt by $48.3 million.
Guidance: Bioventus expects 2025 sales of $560 million—$570 million versus a consensus of $554.62 million, reflecting an organic growth of approximately 6.1% to 8.0% when including the impact of the company’s divestiture of its Advanced Rehabilitation Business, which generated revenue of $45.4 million in 2024.
The company expects 2025 adjusted EPS of $0.64-$0.68 compared to Street estimates of $0.55.
Adjusted EBITDA is expected to be $112 million to $116 million, reflecting 100 basis points in Adjusted EBITDA Margin growth compared to the 2024 and EBITDA margin of 19.0% when using the low end of the 2025 revenue and adjusted EBITDA guidance.
Price Action: BVS stock is up 21.9% at $10.68 at the last check Tuesday.
Read Next:
Photo: Shutterstock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.